Navigation Links
Avexa's Apricitabine Clinical Trial Update

MELBOURNE, Australia--(BUSINESS WIRE)--Jul 5, 2007 - Australian biotechnology company Avexa (ASX:AVX) announced today the completion of apricitabine's controlled, double blinded phase which represents the first 24 week segment of its Phase IIb trial. Patients have now progressed into the open-label section of the trial (weeks 24 to 48) and will continue to receive 800mg apricitabine twice a day as part of their daily treatment regime. The Company expects to release results from the 24 week blinded phase later this quarter.

Avexa also reported that apricitabine continues to maintain its excellent tolerability profile. To date, 14 patients have completed the full 48 weeks on the trial, and 13 of these have elected to continue on apricitabine treatment in an extension study. The longest treated patient has successfully completed more than 18 months of apricitabine therapy. One additional Serious Adverse Event (hospitalization for a minor surgical procedure) has been reported. However, like the three previously reported, this incident was not associated with study drug.

"This data clearly demonstrates that apricitabine is well tolerated in HIV patients. The number of patients requesting to enter the extension study after the 48 week trial to continue treatment with apricitabine is an indicator of the important role that apricitabine will play in the management of HIV. Apricitabine's clinical development remains on schedule and is demonstrating its potential as a safe and effective treatment for HIV," stated Dr. Julian Chick, CEO of Avexa.

Avexa Limited is a Melbourne-based biotechnology company with a focus on research and development of drugs for the treatment of infectious diseases, in particular diseases which have a significant unmet medical need. Avexa has dedicated resources and funding for key projects including antiviral drugs for HIV and an antibiotic alternative for antibiotic-resistant bact
'"/>




Page: 1 2

Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Avexa Apricitabine Clinical Trial Update
(Date:4/23/2015)...  AbbVie (NYSE: ABBV ) has announced that ... its New Drug Application (NDA) and granted priority review ... of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), with ribavirin (RBV). The ... genotype 4 (GT4) hepatitis C virus (HCV) infection. ... being evaluated by the FDA for patients in ...
(Date:4/23/2015)... , April 23, 2015 Once again, ... strengthening our commitment to patient safety. BeaconMedaes, ... fight against infectious disease. The next generation ... Medical gas sensors are now mounted in the assembly, ... need to open ceiling tiles potentially releasing dust spores ...
(Date:4/23/2015)... FRANCISCO , April 23, 2015 Nektar Therapeutics ... the first quarter ended March 31, 2015 on Thursday, April ... Howard Robin , president and chief executive officer, will host ... p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... the conference call can be accessed through a link that ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2Nektar to Announce Financial Results for the First Quarter 2015 on Thursday, April 30, 2015, After Close of U.S.-Based Financial Markets 2
... Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company ... from its consumer trial with Allumera™, a breakthrough cosmetic ... The RevitAll study was performed with a standard ... Allumera™ improves skin appearance, when compared to exposure by ...
... Inc. (Hologic or the Company) (Nasdaq: ... of premium diagnostics products, medical imaging systems and ... of women, announced today the U.S. Food and ... Makena™ (hydroxyprogesterone caproate injection), formerly known as Gestiva™. ...
Cached Medicine Technology:Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 2Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 3Photocure Announces Positive Allumera™ Trial Results for Delivering Significant Skin Appearance Improvements 4FDA Approves Hologic's Makena™ (Formerly Referred to as Gestiva™) Pharmaceutical 2
(Date:4/26/2015)... 2015 Forbes Living is scheduled ... one which is synonymous with clean beaches, sparkling office buildings, ... are major economic influencers in the city on the Pacific ... show are pleased to announce the show will be broadcast ... 3:00 PM PDT. Tune in to find out what the ...
(Date:4/25/2015)... DC (PRWEB) April 26, 2015 The ... Seniors (ACE.S) , a national endeavor to prepare nurses ... adults, is a great success, according to a new ... the program's original funding partners. , The project ... of Philadelphia (CCP), under the direction of Elaine Tagliareni, ...
(Date:4/25/2015)... April 25, 2015 In observance of ... join The Million Nets Pledge, a two-year pledge by ... protect refugee families with one million bednets by 2016. ... work with UN partners to protect children, refugees, and ... , “There has been a large surge in ...
(Date:4/25/2015)... New York (PRWEB) April 25, 2015 ... established for vaginal mesh lawsuits filed against C.R. ... U.S. District Court, Southern District of West Virginia. ... a Scheduling Conference was convened that day, after ... Master Long Form Complaint. The Order directed that ...
(Date:4/25/2015)... Henderson, NV (PRWEB) April 25, 2015 ... Program is still eliciting the excitement of the public ... well into the months of May and June. ... Wellness™ held their biannual tradition of "Special Prayers." More ... who had attended previous Special Prayers and have reported ...
Breaking Medicine News(10 mins):Health News:Forbes Living TV Will Air in San Diego, California 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 2Health News:Hartford Foundation Report Details Success of NLN's Advancing Care Excellence for Seniors (ACE.S) Program 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 4Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 2Health News:Trivedi Master Wellness™ Announces the Resounding Success of their Special Prayers Human Wellness Program 3
... HealthDay Reporter , WEDNESDAY, Nov. 17 (HealthDay News) ... appear to be at higher risk for heart disease. ... with severe atherosclerosis (hardening of the arteries), as measured ... The condition "is emerging as a significant risk ...
... -- Resistance exercise such as weight training affects blood ... benefits, finds a new study. Researchers at the ... (vascular) responses to two types of moderate-intensity workouts: three ... 30 minutes of aerobic cycling. There were significant ...
... named Walter and Eliza Hall Institute researcher Dr Benjamin Kile ... Minister,s Prize for Life Scientist of the Year is awarded ... the potential to advance, human welfare. Dr Kile, ... be presented with the award tonight by the Hon. Kim ...
... Minn. -- With the 2010 election over and new ... to continue the discussion about patient-centered health care. In ... build a high-value health care system, the Mayo Clinic ... entitled "Achieving the Vision: Advancing High-Value ,Health Care." ...
... , WEDNESDAY, Nov. 17 (HealthDay News) -- The structure of ... researchers say. In their study, the investigators found that ... mammals compared to others and that the difference in growth ... the way it connects the mother and baby. The ...
... N.Y., Nov. 17, 2010 Eight states earned a better grade ... 32 others and the District of Columbia saw their preterm birth ... nation saw the first two-year decline in the preterm birth rate, ... rate dropped to 12.3 percent, from the 2006 final rate of ...
Cached Medicine News:Health News:Veterans With PTSD May Be at Higher Risk for Heart Disease 2Health News:Veterans With PTSD May Be at Higher Risk for Heart Disease 3Health News:Resistance Exercise May Offer Different Cardio Benefits 2Health News:Dr. Benjamin Kile named 2010 Australian Life Scientist of the Year 2Health News:Gestational Period Depends on Structure of Placenta: Research 2Health News:Preterm birth rates improve in most states 2
Knot tier...
Knot pusher/suture retriever...
Single step suture passage is made simple with Arthro-Pierce instruments. The low profile, highly sharpened tip allows easy passage through tissue in order to retrieve or apply suture....
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
Medicine Products: